Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487318 | 0.89 | LMNA (0.34) | RIPK1LMNAMAPT | |
| SCHEMBL192711 | 0.79 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL168896 | 0.77 | POLB (0.32) | — | |
| SCHEMBL15720462 | 0.76 | — | — | |
| SCHEMBL4843284 | 0.76 | CA1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL19331829 | 0.74 | DPP4 (0.31) | — | |
| SCHEMBL19331831 | 0.74 | DPP4 (0.31) | — | |
| SCHEMBL3420510 | 0.73 | LMNA (0.31) | LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL12025012 | 0.73 | BRD4 (0.37) | LMNAMAPT | |
| SCHEMBL4554691 | 0.73 | ALDH1A1 (0.34) | LMNACYP2C19ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488177-B1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2498600-B1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2918587-A2 | Filamin a binding anti-inflammatory and analgesic | Pain Therapeutics, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2834221-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | Merck Patent GmbH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8614324-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| WO-2010051497-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051476-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2176219-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009550-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | RIPK1 3935/4885LMNA 223/4885CYP2C19 3632/4885 |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, FPR1 | RIPK1 4092/4885LMNA 174/4885CYP2C19 3850/4885 |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | RIPK1 4312/4885LMNA 216/4885CYP2C19 3771/4885 |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | RIPK1 4459/4885LMNA 4720/4885CYP2C19 114/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | RIPK1 920/4885LMNA 3485/4885CYP2C19 1061/4885 |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | RIPK1 1320/4885LMNA 3611/4885CYP2C19 1163/4885 |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | RIPK1 3935/4885LMNA 223/4885CYP2C19 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.